Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
TLR4	7099	ALCOHOL	CHEMBL545		NCI	11431739
TLR4	7099	SAQUINAVIR	CHEMBL114		NCI	15388451
TLR4	7099	DODECANOATE	CHEMBL108766		DrugBank	10592235
TLR4	7099	MYRISTIC ACID	CHEMBL111077		DrugBank	10592235
TLR4	7099	CHEMBL225157	CHEMBL225157	antagonist	GuideToPharmacologyInteractions, TTD
TLR4	7099	ERITORAN TETRASODIUM (CHEMBL3301672)	CHEMBL3301672	antagonist	ChemblInteractions
TLR4	7099	CHEMBL1232858	CHEMBL1232858		DrugBank	10592235
TLR4	7099	GOLOTIMOD	CHEMBL2103812		DrugBank
TLR4	7099	NELFINAVIR	CHEMBL584		NCI	15388451
TLR4	7099	RITONAVIR	CHEMBL163		NCI	15388451
TLR4	7099	FOLIC ACID	CHEMBL1622		PharmGKB
TLR4	7099	INFLIXIMAB	CHEMBL1201581		NCI	12847679
TLR4	7099	ERITORAN (CHEMBL501259)	CHEMBL501259		TdgClinicalTrial, DrugBank	17803912, 16820585

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
TLR4	rs4986790	AA	Pertussis vaccines	efficacy	yes	10-year follow-up for a booster dose of acellular pertussis vaccine. Original vaccine given at 3, 4, 5 and 24 months old. No pertussis had occurred in any patients at this 10-year point. The fold increase in antibody response to pertussis toxin after vaccination was significantly lower in subjects with the AG or GG genotypes as compared to those with the AA genotype (wild-type); 55% vs 86%, respectively.	Genotype AA is associated with increased response to Pertussis vaccines in children as compared to genotypes AG + GG.	22383676	1444702987
TLR4	TLR4 haplotype		tacrolimus	metabolism/PK	yes	The poor metabolizer group consisted of 1) recipients with genotype CC at rs776746 (CYP3A5) with livers from 2) donors with a genotype of CC at rs776746 (CYP3A5) and a genotype of CC at rs1927907 (TLR4). The extensive metabolizer group consisted of 1) recipients with a rs776746 (CYP3A4) TT/CT genotype with livers from 2) donors with a genotype of TT/CT at rs776746 (CYP3A5) and a genotype of TT/CT at rs1927907 (TLR4). The intermediate metabolizer groups consisted of other genotype combinations at rs776746 and rs1927907.	TLR4 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to TLR4 intermediate metabolizer and normal metabolizer.	24820765	1184754633
TLR4	rs2770150	GG	Pertussis vaccines	efficacy	yes	Patients with the GG genotype had a lower pertussis toxin-specific immunoglobulin G (PT-IgG) titer following whole-cell pertussis vaccination as compared to those with the AG genotype. The IgG antibody titer against PT correlates with protection against disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with decreased response to Pertussis vaccines in children as compared to genotype AG.	17699831	1444702155
TLR4	rs5030728	AA + AG	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for all cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype GG.	24776844	1296666768
TLR4	rs1927907	T	tacrolimus	metabolism/PK	no	This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients.	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.	29318894	1449163120
TLR4	rs1927907	CC	tacrolimus	metabolism/PK	yes	The genotype of liver transplant donors as well as the genotype of liver transplant recipients was evaluated for its effect on dose adjusted trough concentration of tacrolimus on recipients. The CT+TT genotype of donors was associated with significantly lower dose adjusted trough concentrations of tacrolimus as compared to the CC genotype. The genotype of the donor was not associated with dose adjusted trough concentration of tacrolimus in the recipient.	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	24820765	1184754606